TQ80 Stock Overview
A biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Theratechnologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.28 |
| 52 Week High | CA$2.58 |
| 52 Week Low | CA$0.96 |
| Beta | 0.90 |
| 1 Month Change | -5.00% |
| 3 Month Change | 28.81% |
| 1 Year Change | 109.17% |
| 3 Year Change | -75.43% |
| 5 Year Change | -63.92% |
| Change since IPO | -81.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TQ80 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | 0.5% | 0.05% |
| 1Y | 109.2% | -12.9% | 15.2% |
Return vs Industry: TQ80 exceeded the German Biotechs industry which returned -12.9% over the past year.
Return vs Market: TQ80 exceeded the German Market which returned 15.2% over the past year.
Price Volatility
| TQ80 volatility | |
|---|---|
| TQ80 Average Weekly Movement | 32.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: TQ80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TQ80's weekly volatility has increased from 18% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 103 | Paul Lévesque | www.theratech.com |
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
Theratechnologies Inc. Fundamentals Summary
| TQ80 fundamental statistics | |
|---|---|
| Market cap | €108.59m |
| Earnings (TTM) | -€3.27m |
| Revenue (TTM) | €78.23m |
Is TQ80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TQ80 income statement (TTM) | |
|---|---|
| Revenue | US$88.67m |
| Cost of Revenue | US$18.65m |
| Gross Profit | US$70.02m |
| Other Expenses | US$73.73m |
| Earnings | -US$3.71m |
Last Reported Earnings
Feb 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 78.97% |
| Net Profit Margin | -4.18% |
| Debt/Equity Ratio | -202.2% |
How did TQ80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 02:27 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/02/28 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Theratechnologies Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zhang | BMO Capital Markets U.S. (Historical) |
| Douglas Loe | Byron Capital Markets |
| Dewey Steadman | Canaccord Genuity |